Immunosuppressive
PreclinicalSmall molecule
Chiesi Farmaceutici S.p.A.Immunosuppressive is one of 94 small molecule programs targeting Metabolic Syndrome. It is currently in Preclinical.
3
Indications
3
Total Trials
0
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
309 competitors in COVID-19
#DrugCompanyPhaseTrials
1Aimovig
AmgenPreclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Other Tkis
BayerPreclinical
Immunosuppressive
Chiesi Farmaceutici S.p.A.Preclinical
Serology
UUniversity Hospital Center of Martinique
Preclinical
Pfizer-Biontech COVID-19 MRNA Vaccine
PfizerPreclinical
Tpa
UUniversity of Florida
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
Huashi Baidu Granule
XXiyuan Hospital of China Academy of Chinese Medical Sciences
Preclinical
Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Kidney Transplant1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Immunosuppressive. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company